Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Aviptadil in COVID-19 Patients at High Risk for ARDS
NCT04536350Phase 2Terminated
- Start
- May 2021
- Primary completion
- Jun 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of aviptadil in coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS). Started May 2021; status: terminated.
02
Drugs
aviptadil
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04536350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04536350.